Zenas BioPharma Balance Sheet Health
Financial Health criteria checks 6/6
Zenas BioPharma has a total shareholder equity of $359.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $403.4M and $44.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$386.80m |
| Equity | US$359.44m |
| Total liabilities | US$44.00m |
| Total assets | US$403.43m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ZBIO's short term assets ($393.8M) exceed its short term liabilities ($44.0M).
Long Term Liabilities: ZBIO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ZBIO is debt free.
Reducing Debt: ZBIO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZBIO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ZBIO has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 7.9% each year.